We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App





New Study Reveals Rapid Sepsis Test Drives 56% Boost in ED Discharges

By LabMedica International staff writers
Posted on 31 Jul 2025

Every year, emergency departments (EDs) in the United States record over 155 million visits, with around 20% of adults showing signs of potentially serious infections. More...

One of the most critical choices emergency clinicians must make is determining which of these patients has sepsis and which do not. In situations where time is of the essence, the ability to swiftly and accurately rule out sepsis can significantly influence patient outcomes, the quality of care, hospital finances, and the overall efficiency of the healthcare system.

At the same time, overcrowding in EDs continues to put pressure on hospital operations and affect patient satisfaction. Over a 12-month span, average ED boarding times rose from 167 to 175 minutes, while the percentage of patients leaving without being seen increased from 1.1% to 2.1%, raising serious safety concerns. In such a context, being overly cautious and admitting patients out of concern for sepsis—though done with good intentions—can worsen crowding and slow down treatment for others, including those who are actually septic. Now, new multicenter study data presented at ADLM 2025 reveal that targeted sepsis testing at triage in the ED may be key to preserving inpatient bed capacity for the most severe patients.

Cytovale’s (San Francisco, CA, USA) IntelliSep is a rapid diagnostic tool for sepsis that supports emergency clinicians in making more confident decisions by quickly assessing patients’ sepsis risk. This U.S. Food and Drug Administration-cleared diagnostic, which provides results in roughly eight minutes from a standard blood draw, can be used at the triage stage to stratify patients based on their risk. The quick results help clinicians distinguish those who can be safely discharged from those needing urgent care and possible hospitalization. The study shared at ADLM 2025 involved 4,650 patients showing signs and symptoms of infection, who were tested with IntelliSep over a four-month period at four hospitals.

Using IntelliSep's rapid host-response test led to a 56% relative increase in discharges from the ED among patients identified as low risk, while simultaneously reducing the use of inpatient beds—without causing a rise in return visits. By applying this risk assessment tool early during triage, clinicians were able to avoid unnecessary admissions and discharge patients more confidently. The findings emphasize that smarter, data-driven sepsis evaluations at triage can have a direct effect on hospital capacity by boosting the number of safe discharge decisions.

Related Links:
Cytovale


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
Pipette
Accumax Smart Series
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.